Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02855125 · ClinicalTrials.gov registry record · Phase 2
A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1
A Phase 2 study, sponsored by Taiho Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 128
- Enrollment target
NCT02855125 is a Phase 2 study that has completed, run by Taiho Oncology. The registered enrollment target is 128 participants.
The verdict
NCT02855125, a Phase 2 study, has completed, sponsored by Taiho Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 128 participants
- Enrollment target
Study Summary
This is a randomized, open-label, Phase 2 study of TAS-114 administered in combination with S-1, to investigate the efficacy, safety and tolerability of the TAS-114/S-1 regimen in patients with advanced or metastatic NSCLC. The study will be conducted internationally in 2 regions: Asian \[Japan\] and Western \[Europe and US\]. Patients will be randomized into TAS-114/S-1 arm versus S-1 control arm in a 1:1 ratio.
Interventions
- DRUG S-1
- DRUG TAS-114
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2016-08-29 |
| Est. Completion | 2017-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02855125
The ClinicalTrials.gov registry entry for NCT02855125 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which S-1 is the first listed.
NCT02855125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02855125 about?
NCT02855125 is a clinical study titled "A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1". This is a randomized, open-label, Phase 2 study of TAS-114 administered in combination with S-1, to investigate the efficacy, safety and tolerability of the TAS-114/S-1 regimen in patients with advanced or metastatic NSCLC. The study will be conducted internationally in 2 regions: Asian \[Japan\] a...
What is the current status of trial NCT02855125?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2016-08-29. Estimated completion is 2017-11-30.
What interventions are being tested in trial NCT02855125?
The interventions under investigation include: S-1 (DRUG), TAS-114 (DRUG).
Who is sponsoring clinical trial NCT02855125?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.